BofA/Merrill Lynch Starts ProNAi Therapeutics (DNAI) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall St gains as AI earnings lift tech, inflation data supports rate-hold bets
- Oil prices dip as investors weigh lower demand forecasts against US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Wedbush Starts ProNAi Therapeutics (DNAI) at Outperform
August 10, 2015 7:34 AM EDTWedbush initiates coverage on ProNAi Therapeutics (NASDAQ: DNAI) with a Outperform rating and a price target of $36.00.
Analyst David Nierengarten commented, "DNAI is a clinical-stage biotech company developing a novel therapeutic platform based on DNA interference (DNAi). ProNAi's lead candidate, PNT2258, is a... More
Jefferies Starts ProNAi Therapeutics (DNAI) at Buy
August 10, 2015 7:04 AM EDTJefferies initiates coverage on ProNAi Therapeutics (NASDAQ: DNAI) with a Buy rating and a price target of $37.00.
Analyst Brian Abrahams commented, "ProNAi is developing PNT2258, a Bcl2-directed oligonucleotide, in ph.II for hematological cancers. We believe DNAI is undervalued based on 2258s... More
